Results 121 to 130 of about 166 (149)
Some of the next articles are maybe not open access.
Journal of European Economic History
The global pharmaceutical industry has undergone a paradigm shift from the dominance of blockbuster small-molecule drugs to biologics and biosimilars. This transformation is driven by patent expirations, escalating research and development (R&D) costs, advancements in biotechnology, and the increasing burden of chronic diseases.
openaire +1 more source
The global pharmaceutical industry has undergone a paradigm shift from the dominance of blockbuster small-molecule drugs to biologics and biosimilars. This transformation is driven by patent expirations, escalating research and development (R&D) costs, advancements in biotechnology, and the increasing burden of chronic diseases.
openaire +1 more source
Biosimilars Pharmaceutical Market in India: Current Status, Challenges and Future Perspective
Bioscience Biotechnology Research Communications, 2021openaire +1 more source
P & T : a peer-reviewed journal for formulary management, 2014
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
openaire +1 more source
Unlike a generic drug, a "generic" biologic won't be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the "biosimilars" that will soon appear on the market.
openaire +1 more source
The Impact of Mandatory Nonmedical Switching From Originator to Biosimilar Insulin Glargine
Clinical Therapeutics, 2022Colin Dormuth, Anat Fisher, Jason Kim
exaly
Clinical safety of biosimilar recombinant human erythropoietins
Expert Opinion on Drug Safety, 2012Karen Macdonald, Ivo Abraham
exaly